The ALLHAT Lipid Lowering Trial—Less Is Less
The ALLHAT Lipid Lowering Trial—Less Is Less
No Thumbnail Available
Publication or External Link
Date
2002
Authors
Pasternak, Richard C.
Advisor
Citation
Pasternak, Richard C. (2002) The ALLHAT Lipid Lowering Trial—Less Is Less. JAMA, 288 (23). pp. 3042-3044.
DRUM DOI
Abstract
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),1 published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,2 followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs "usual care" in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.2 Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . .